Calcium channel antagonists in the treatment of coronary artery disease: fundamental pharmacological properties relevant to clinical use. (Q40940976)

25 September 2017

1 reference

title

Calcium channel antagonists in the treatment of coronary artery disease: fundamental pharmacological properties relevant to clinical use. (English)

1 reference

25 September 2017

coronary artery disease

1 reference

Opie LH

1

1 reference

25 September 2017

1 January 1996

1 reference

Progress in Cardiovascular Diseases

25 September 2017

1 reference

25 September 2017

38

1 reference

25 September 2017

4

1 reference

25 September 2017

273-290

1 reference

Appraisal of the physiological relevance of two hypothesis for the mechanism of calcium release from the mammalian cardiac sarcoplasmic reticulum: calcium-induced release versus charge-coupled release

25 September 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0033-0620%2896%2980014-4

7 January 2021

Targeted ablation of the phospholamban gene is associated with markedly enhanced myocardial contractility and loss of beta-agonist stimulation

1 reference

https://api.crossref.org/works/10.1016%2FS0033-0620%2896%2980014-4

7 January 2021

Two kinds of calcium channels in canine atrial cells. Differences in kinetics, selectivity, and pharmacology

1 reference

https://api.crossref.org/works/10.1016%2FS0033-0620%2896%2980014-4

7 January 2021

T-type Ca2+ current is expressed in hypertrophied adult feline left ventricular myocytes

1 reference

https://api.crossref.org/works/10.1016%2FS0033-0620%2896%2980014-4

7 January 2021

Single amino acid substitutions within the ion permeation pathway alter single-channel conductance of the human L-type cardiac Ca2+ channel.

1 reference

https://api.crossref.org/works/10.1016%2FS0033-0620%2896%2980014-4

7 January 2021

Calcium channel β-subunit binds to a conserved motif in the I–II cytoplasmic linker of the α1-subunit

1 reference

https://api.crossref.org/works/10.1016%2FS0033-0620%2896%2980014-4

7 January 2021

Acceleration of activation and inactivation by the β subunit of the skeletal muscle calcium channel

1 reference

https://api.crossref.org/works/10.1016%2FS0033-0620%2896%2980014-4

7 January 2021

International Society and Federation of Cardiology: Working Group on Classification of Calcium Antagonists for Cardiovascular Disease

1 reference

https://api.crossref.org/works/10.1016%2FS0033-0620%2896%2980014-4

7 January 2021

Classification of calcium channels and calcium antagonists: progress report

1 reference

https://api.crossref.org/works/10.1016%2FS0033-0620%2896%2980014-4

7 January 2021

Identification of 1,4-dihydropyridine binding domains within the primary structure of the alpha 1 subunit of the skeletal muscle L-type calcium channel

1 reference

https://api.crossref.org/works/10.1016%2FS0033-0620%2896%2980014-4

7 January 2021

Azidobutyryl clentiazem, a new photoactivatable diltiazem analog, labels benzothiazepine binding sites in the alpha 1 subunit of the skeletal muscle calcium channel

1 reference

https://api.crossref.org/works/10.1016%2FS0033-0620%2896%2980014-4

7 January 2021

The Role of Sodium - Calcium Exchange during the Cardiac Action Potential

1 reference

https://api.crossref.org/works/10.1016%2FS0033-0620%2896%2980014-4

7 January 2021

Tissue-specific expression of calcium channels

1 reference

https://api.crossref.org/works/10.1016%2FS0033-0620%2896%2980014-4

7 January 2021

Subunit-dependent modulation of recombinant L-type calcium channels. Molecular basis for dihydropyridine tissue selectivity

1 reference

https://api.crossref.org/works/10.1016%2FS0033-0620%2896%2980014-4

7 January 2021

Mechanisms of action of transmitters and other substances on smooth muscle

1 reference

https://api.crossref.org/works/10.1016%2FS0033-0620%2896%2980014-4

7 January 2021

Signal transduction by G proteins in cardiac tissues

1 reference

https://api.crossref.org/works/10.1016%2FS0033-0620%2896%2980014-4

7 January 2021

Contribution of endogenous generation of endothelin-1 to basal vascular tone

1 reference

https://api.crossref.org/works/10.1016%2FS0033-0620%2896%2980014-4

7 January 2021

Endothelin action on vascular smooth muscle involves inositol trisphosphate and calcium mobilization

1 reference

https://api.crossref.org/works/10.1016%2FS0033-0620%2896%2980014-4

7 January 2021

Angiotensin II increases spontaneous contractile frequency and stimulates calcium current in cultured neonatal rat heart myocytes: insights into the underlying biochemical mechanisms

1 reference

https://api.crossref.org/works/10.1016%2FS0033-0620%2896%2980014-4

7 January 2021

Angiotensin II facilitates sympathetic transmission in rat hind limb circulation.

1 reference

https://api.crossref.org/works/10.1016%2FS0033-0620%2896%2980014-4

7 January 2021

Myocardial alpha 1-adrenoceptors mediate positive inotropic effect and changes in phosphatidylinositol metabolism. Species differences in receptor distribution and the intracellular coupling process in mammalian ventricular myocardium

1 reference

https://api.crossref.org/works/10.1016%2FS0033-0620%2896%2980014-4

7 January 2021

Effect of the angiotensin-converting enzyme inhibitor, perindoprilat, and of angiotensin-II on the transient inward current of rabbit ventricular myocytes

1 reference

https://api.crossref.org/works/10.1016%2FS0033-0620%2896%2980014-4

7 January 2021

Should calcium antagonists be used after myocardial infarction? Ischemia selectivity versus vascular selectivity

1 reference

https://api.crossref.org/works/10.1016%2FS0033-0620%2896%2980014-4

7 January 2021

Ischemia-selectivity: a new concept of cardioprotection by calcium antagonists

1 reference

https://api.crossref.org/works/10.1016%2FS0033-0620%2896%2980014-4

7 January 2021

Glucose flux rate regulates onset of ischemic contracture in globally underperfused rat hearts

1 reference

https://api.crossref.org/works/10.1016%2FS0033-0620%2896%2980014-4

7 January 2021

Modulation of severity of reperfusion stunning in the isolated rat heart by agents altering calcium flux at onset of reperfusion

1 reference

https://api.crossref.org/works/10.1016%2FS0033-0620%2896%2980014-4

7 January 2021

Problem of measuring the positive inotropic property of a vasodilating drug: an illustration using felodipine

1 reference

https://api.crossref.org/works/10.1016%2FS0033-0620%2896%2980014-4

7 January 2021

Converting-enzyme inhibition buffers the counter-regulatory response to acute administration of nicardipine

1 reference

https://api.crossref.org/works/10.1016%2FS0033-0620%2896%2980014-4

7 January 2021

Adrenergic activity and left ventricular function during treatment of essential hypertension with calcium antagonists

1 reference

https://api.crossref.org/works/10.1016%2FS0033-0620%2896%2980014-4

7 January 2021

Normalization of left ventricular mass and associated changes in neurohormones and atrial natriuretic peptide after 1 year of sustained nifedipine therapy for severe hypertension

1 reference

https://api.crossref.org/works/10.1016%2FS0033-0620%2896%2980014-4

7 January 2021

Antihypertensive effect of felodipine associated with persistent sympathetic activation and minimal regression of left ventricular hypertrophy

1 reference

https://api.crossref.org/works/10.1016%2FS0033-0620%2896%2980014-4

7 January 2021

Proischemic complications of dihydropyridine calcium channel blockers

1 reference

https://api.crossref.org/works/10.1016%2FS0033-0620%2896%2980014-4

7 January 2021

A proischaemic action of nisoldipine: relationship to a decrease in perfusion pressure and comparison to dipyridamole

1 reference

https://api.crossref.org/works/10.1016%2FS0033-0620%2896%2980014-4

7 January 2021

Double-blind, dose-response, placebo-controlled multicenter study of nisoldipine. A new second-generation calcium channel blocker in angina pectoris

1 reference

https://api.crossref.org/works/10.1016%2FS0033-0620%2896%2980014-4

7 January 2021

Efficacy, duration and mechanism of action of nifedipine in stable exercise-induced angina pectoris

1 reference

https://api.crossref.org/works/10.1016%2FS0033-0620%2896%2980014-4

7 January 2021

Role of calcium channel blockers in experimental exercise-induced ischemia

1 reference

https://api.crossref.org/works/10.1016%2FS0033-0620%2896%2980014-4

7 January 2021

Vasoconstriction of stenotic coronary arteries during dynamic exercise in patients with classic angina pectoris: reversibility by nitroglycerin

1 reference

https://api.crossref.org/works/10.1016%2FS0033-0620%2896%2980014-4

7 January 2021

The beneficial effect of a calcium channel blocker, Diltiazem, on the ischemic-reperfused heart

1 reference

https://api.crossref.org/works/10.1016%2FS0033-0620%2896%2980014-4

7 January 2021

Protective effect of pretreatment with verapamil, nifedipine and propranolol on mitochondrial function in the ischemic and reperfused myocardium

1 reference

https://api.crossref.org/works/10.1016%2FS0033-0620%2896%2980014-4

7 January 2021

Calcium antagonists and the ischemic myocardium

1 reference

https://api.crossref.org/works/10.1016%2FS0033-0620%2896%2980014-4

7 January 2021

Calcium channel antagonists. Part II: Use and comparative properties of the three prototypical calcium antagonists in ischemic heart disease, including recommendations based on an analysis of 41 trials

1 reference

https://api.crossref.org/works/10.1016%2FS0033-0620%2896%2980014-4

7 January 2021

Diltiazem inhibition of sodium-induced calcium release. Effects on energy metabolism of heart mitochondria

1 reference

https://api.crossref.org/works/10.1016%2FS0033-0620%2896%2980014-4

7 January 2021

Reduction of endothelin levels by the dihydropyridine calcium antagonist nisoldipine and a 'natural factor' in cultured human endothelial cells

1 reference

https://api.crossref.org/works/10.1016%2FS0033-0620%2896%2980014-4

7 January 2021

A controlled clinical trial to assess the effect of a calcium channel blocker on the progression of coronary atherosclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS0033-0620%2896%2980014-4

7 January 2021

A preliminary study of diltiazem in the prevention of coronary artery disease in heart-transplant recipients

1 reference

https://api.crossref.org/works/10.1016%2FS0033-0620%2896%2980014-4

7 January 2021

Comparative antioxidant activities of propranolol, nifedipine, verapamil, and diltiazem against sarcolemmal membrane lipid peroxidation

1 reference

https://api.crossref.org/works/10.1016%2FS0033-0620%2896%2980014-4

7 January 2021

A new method to study activated oxygen species induced damage in cardiomyocytes and protection by Ca2+-antagonists

1 reference

https://api.crossref.org/works/10.1016%2FS0033-0620%2896%2980014-4

7 January 2021

Effects of verapamil and nisoldipine on human platelets: in vivo and in vitro studies

1 reference

https://api.crossref.org/works/10.1016%2FS0033-0620%2896%2980014-4

7 January 2021

Response of the coronary vasculature to myocardial hypertrophy

1 reference

https://api.crossref.org/works/10.1016%2FS0033-0620%2896%2980014-4

7 January 2021

Reversal of left ventricular hypertrophy in hypertensive patients. A metaanalysis of 109 treatment studies

1 reference

https://api.crossref.org/works/10.1016%2FS0033-0620%2896%2980014-4

7 January 2021

Comparison of the effects of isradipine and lisinopril on left ventricular structure and function in essential hypertension

1 reference

https://api.crossref.org/works/10.1016%2FS0033-0620%2896%2980014-4

7 January 2021

Relation of regression of left ventricular hypertrophy to changes in ambulatory blood pressure after long-term therapy with perindopril versus nifedipine

1 reference

https://api.crossref.org/works/10.1016%2FS0033-0620%2896%2980014-4

7 January 2021

Effect of nifedipine on coronary capillary geometry in normotensive and hypertensive rats

1 reference

https://api.crossref.org/works/10.1016%2FS0033-0620%2896%2980014-4

7 January 2021

Update of effects of calcium antagonists in myocardial infarction or angina in light of the second Danish Verapamil Infarction Trial (DAVIT-II) and other recent studies.

1 reference

https://api.crossref.org/works/10.1016%2FS0033-0620%2896%2980014-4

7 January 2021

The effect of diltiazem on mortality and reinfarction after myocardial infarction

1 reference

https://api.crossref.org/works/10.1016%2FS0033-0620%2896%2980014-4

7 January 2021

Microvascular mechanisms involved in calcium antagonist edema formation

1 reference

https://api.crossref.org/works/10.1016%2FS0033-0620%2896%2980014-4

7 January 2021

A comparison of isradipine and felodipine in Australian patients with hypertension: focus on ankle oedema. The Physician's Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0033-0620%2896%2980014-4

7 January 2021

Calcium-channel blockade with nifedipine and angiotensin converting-enzyme inhibition with captopril in the therapy of patients with severe primary hypertension

1 reference

https://api.crossref.org/works/10.1016%2FS0033-0620%2896%2980014-4

7 January 2021

Hemodynamics of nicardipine in coronary artery disease

1 reference

https://api.crossref.org/works/10.1016%2FS0033-0620%2896%2980014-4

7 January 2021

Comparison of the efficacy and safety of once-daily versus twice-daily formulations of diltiazem in the treatment of systemic hypertension. The Canadian Multicenter Diltiazem-CD Hypertension Trial Group

1 reference

https://api.crossref.org/works/10.1016%2FS0033-0620%2896%2980014-4

7 January 2021

Calcium channel antagonists. Part IV: Side effects and contraindications drug interactions and combinations

1 reference

https://api.crossref.org/works/10.1016%2FS0033-0620%2896%2980014-4

7 January 2021

10.1016/S0033-0620(96)80014-4

Identifiers

DOI

1 reference

25 September 2017

1 reference

PubMed ID

8552787